Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 102, Issue 3, Pages 502-510Publisher
WILEY
DOI: 10.1002/cpt.630
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [U01 HL105198, U01 GM92666, R24 GM115264, P50 GM115279, GM61374, U01 GM92655, U19 HL065962, RO1 GM28157, U19 GM61388, KL2 RR024151, U01 GM074492, U01 HG007269, UL1 TR 000064, UL1 TR001427]
- NIH/National Cancer Institute [CA 21765]
- American Lebanese Syrian Associated Charities
- American Heart Association [14POST20100054]
- NIH [L30 HL110279]
Ask authors/readers for more resources
Numerous pharmacogenetic clinical guidelines and recommendations have been published, but barriers have hindered the clinical implementation of pharmacogenetics. The Translational Pharmacogenetics Program(TPP) of the National Institutes of Health (NIH) Pharmacogenomics Research Network was established in 2011 to catalog and contribute to the development of pharmacogenetic implementations at eight US healthcare systems, with the goal to disseminate realworld solutions for the barriers to clinical pharmacogenetic implementation. The TPP collected and normalized pharmacogenetic implementationmetrics through June 2015, including gene-drug pairs implemented, interpretations of alleles and diplotypes, numbers of tests performed and actionable results, and workflow diagrams. TPP participant institutions developed diverse solutions to overcome many barriers, but the use of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provided some consistency among the institutions. The TPP also collected some pharmacogenetic implementation outcomes (scientific, educational, financial, and informatics), which may informhealthcare systems seeking to implement their own pharmacogenetic testing programs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available